BridgeMD
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN).
EU CTIS ID: 2024-514135-17-00
What this study is testing
To evaluate the efficacy of povetacicept compared with placebo in reducing proteinuria; To evaluate the efficacy of povetacicept compared with placebo in preserving renal function.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Diagnosed IgAN, with biopsy confirmation
- 2. 24 hour proteinuria excretion greater than or equal to (≥)1.0 gram per day (g/day) or 24-hour uPCR ≥0.75 gram per gram (g/g).
- 3. Estimated glomerular filtration rate (eGFR) - ≥ 30 mL/min/1.73m2.
- 4. Stable angiotensin converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARBs) as per protocol specification.
You likely can't join if
- 1. Have received any immunosuppressive treatment or procedures (including corticosteroids, oral immunosuppressive agents, B cell or plasma cell targeted therapies, complement targeted therapies, herbal medicines per protocol, and tonsillectomy) within a wash-out period per protocol.
- 2. Rapidly progressive glomerulonephritis with eGFR reduction >50% within 12 weeks of the start of screening.
- 3. Other protocol defined Inclusion/Exclusion criteria may apply.
The study team makes the final eligibility decision.
Where it's taking place
- Taiwan
- United Kingdom
- United States
- Mexico
- Australia
- Canada
- China
- Israel
- Saudi Arabia
- Brazil
- Korea, Republic of
- Turkey
- Hong Kong
- Japan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Taiwan; United Kingdom; United States; Mexico; Australia; Canada and 8 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.